
    
      This will be an Open-label, Multicenter, study in patients with PBA and dementia, stroke or
      TBI. Patients with a clinical diagnosis of PBA and who meet all other inclusion and exclusion
      criteria will be eligible to participate and receive NUEDEXTA for 12 weeks.

      Males and females patients with a minimum age of 18 years, a clinical diagnosis of
      Pseudobulbar Affect and a documented diagnosis of neurologic disease or brain injury, will be
      enrolled in this study.

      The primary effectiveness endpoint is the mean change in the Center for Neurologic
      Study-Lability scale (CNS-LS). Secondary objectives include measures to evaluate treatment
      outcomes.
    
  